Aptamer secures contract Eetension with top 5 pharma partner

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has announced a contract extension, entailing a new work order, with a top 5 global pharmaceutical company.

As previously announced in the Company’s commercial trading update on 6 November 2024, following the successful completion of a project for the development of Optimer® binders to support an ELISA assay, Aptamer has now secured an extension to this project.

This paid-for extension involves the conversion of these binders into a fully functional ELISA assay. This progression demonstrates the efficacy of Aptamer’s Optimer® technology in meeting the partner’s requirements and advances the project into assay development.

Aptamer retains ownership of the intellectual property associated with these binders, positioning the Company to potentially establish commercialisation licenses in the future. This extension underscores the Group’s ability to deliver high-quality results that foster ongoing partnerships with leading pharmaceutical companies.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group said: “We are delighted to have successfully completed the initial binder development phase for this top 5 pharma partner and to now extend our collaboration into assay conversion.

This milestone not only validates the performance of our Optimer® platform but also highlights its potential for broader applications in diagnostics and therapeutics. Retaining IP ownership provides us with opportunities for future licensing revenues, aligning with our strategy to build long-term value through repeat business and commercialisation pathways.

We look forward to providing further updates as this and other projects progress.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

    Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event.

    Aptamer signs contract with Metir for Cryptosporidium detection binders

    Aptamer has signed a new contract with Metir plc to develop Optimer® binders for the rapid detection of Cryptosporidium parvum oocysts in Metir’s Pathogen Detector platform.

    Aptamer signs therapeutic development deal with Invizius

    Aptamer Group has entered a new agreement with Invizius to develop Optimer® binders targeting the complement system for inflammatory and autoimmune diseases. The collaboration aims to enhance Invizius’ H-Guard® platform, currently in Phase 2 trials, by providing safer and more precise therapies, including potential treatments for IgA nephropathy.

    Aptamer advances enzyme modulation projects and expands pharma collaboration

    Aptamer Group announced progress on its Optimer® enzyme modulation projects, including a 10-year non-exclusive licensing deal forecast to cover around 15% of annual overheads and further agreements under discussion with global enzyme distributors.

    Aptamer secures contract Eetension with top 5 pharma partner

    Aptamer has extended its collaboration with a top 5 global pharmaceutical company to advance Optimer® binders into a fully functional ELISA assay. The agreement builds on the successful completion of the initial binder development phase, with Aptamer retaining IP ownership to support future commercialisation opportunities.

    Aptamer Group to host technical development update webinar

    Aptamer will hold a webinar on 14 August 2025 at 6:00 pm BST, led by Chief Scientific Officer Dr David Bunka, to present the latest data and progress across its technical development programmes.

      Search

      Search